Phase III randomised trial to evaluate the benefit of adjuvant hormonal treatment with leuprorelin acetate (Eligard(R) 45 mg) for 24 months after radical prostatectomy in patients with high risk of recurrence.

Trial Profile

Phase III randomised trial to evaluate the benefit of adjuvant hormonal treatment with leuprorelin acetate (Eligard(R) 45 mg) for 24 months after radical prostatectomy in patients with high risk of recurrence.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2015

At a glance

  • Drugs Leuprorelin (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms AFU-GETUG20
  • Sponsors UNICANCER
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top